TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
RARE

Ultragenyx

Healthcare · Biotechnology

14.50$ +12.6% vs. previous close Closing price · As of: Sep 17, 2026

Investor relations

Report Dates

Investor relations overview for Ultragenyx (RARE): report dates, earnings surprises, earnings call transcripts and the latest headlines. The next report is scheduled for 11/03/2026.

Next report 11/03/2026
Last report 08/04/2026
Earnings surprise by quarter (%)
Q3 23 · -11.0 % 23 Q4 23 · 5.6 % 23 Q1 24 · -18.0 % 24 Q2 24 · 6.8 % 24 Q3 24 · 4.8 % 24 Q4 24 · -9.5 % 24 Q1 25 · 4.3 % 25 Q2 25 · 11.4 % 25 Q3 25 · -49.6 % 25 Q4 25 · -10.3 % 25 Q1 26 · -5.5 % 26 Q2 26 · 29.1 % 26

EPS estimate beaten

Full history 14 of 51 quarters (27%)
Last 16 quarters 6 of 16 quarters (38%)

Earnings Call Transcripts

Search all transcripts →

  • 08/04/2026 Earnings Call Q2 2026 Open →
  • 05/06/2026 Earnings Call Q1 2026 Open →
  • 02/12/2026 Earnings Call Q4 2025 Open →
  • 11/05/2025 Earnings Call Q3 2025 Open →
  • 08/06/2025 Earnings Call Q2 2025 Open →
  • 05/06/2025 Earnings Call Q1 2025 Open →
  • 02/13/2025 Earnings Call Q4 2024 Open →
  • 11/05/2024 Earnings Call Q3 2024 Open →
  • 08/02/2024 Earnings Call Q2 2024 Open →
  • 05/02/2024 Earnings Call Q1 2024 Open →

News on This Stock

  • 09/17/2026 Ultragenyx Pharmaceutical Inc. (RARE): Other Events · sec.gov Open ↗
  • 09/02/2026 Ultragenyx Pharmaceutical Inc. (RARE): Other Events · sec.gov Open ↗
  • 08/19/2026 Ultragenyx Pharmaceutical Inc. (RARE): Other Events · sec.gov Open ↗
  • 08/11/2026 Ultragenyx Pharmaceutical Inc. (RARE): Other Events · sec.gov Open ↗
  • 08/04/2026 Ultragenyx Pharmaceutical Inc. (RARE): Results of Operations and Financial Condition; Financial Statements and Exhibits · sec.gov Open ↗

Automatically matched wire and portal stories; external links open the original source.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Transcripts: transcript archive

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?